Editor: Professor L Leibovici

To the editor

Superinfections, including invasive pulmonary aspergillosis (IPA), are well-known complications of severe viral pneumonia in critically ill patients \[[@bib1]\].

Pathological studies of patients with severe COVID-19 associated acute respiratory distress syndrome (ARDS), reported a diffuse alveolar damage combined with intra-alveolar neutrophilic infiltration and vascular congestion, assuming an impaired mucociliary activity which might pave the way for secondary infections \[[@bib2], [@bib3]\].

Our report of two critically ill patients suggests that IPA might be a relevant complication of severe COVID-19 pneumonia in analogy to experiences in severe influenza pneumonia.

Both patients without typical risk factors for IPA e.g. steroid medication or other immunospuppression were admitted from a secondary-care- hospital with pneumonia caused by COVID-19 to our ICU after progression to severe ARDS.

While in the initial bronchoalveolar lavage (BAL) of both patients only COVID-19 was found (Influenza and respiratory syncytial virus PCR negative), a follow-up BAL because of ongoing fever few days later (day 5 and 6 after ICU admission) additionally showed elevated Galactomannan (GM) and growth of *Aspergillus fumigatus* in standard culture, suggesting invasive pulmonary aspergillosis (IPA) (see [table 1](#tbl1){ref-type="table"} ). All patients received a chest computed tomography (CT) scan before ICU admittance with typical signs for COVID-19 pneumonia but no specific signs for IPA. Follow up CT scans were not performed based on safety reasons.Table 1Results of Glactomannan (BAL and serum) and standard cultureTable 1Patient 1(80 years, male, suspected pulmonary fibrosis)Patient 2(70 years, male, no risk factors)Galactomannan from BAL (ODI; normal range \<1.0)6.36.1Galactomannan from Serum(ODI; normal range \<0.5)1.5\<0.5Standard culture*Aspergillus fumigatusAspergillus fumigatus*SARS-CoV-2(at follow up)positivepositiveLaboratory parameters mean at IPA diagnosis-CrP (mg/dl)265.1-IL6 (pg/ml)46082-PCT (ng/ml)3.70.4-D-Dimer (μg/l)482014151-LDH (U/l)481530-Leukozyte count (G/l)10.38014550-Lymphocytes (%)157Renal failureYesYesClassical risk factors for invasive pulmonary aspergillosisNoNo[^1]

The timepoint of IPA-diagnosis is inline with previous studies which demonstrated a median time to IPA diagnosis between 3 and 9 days after ICU-admission of patients with severe influenza pneumonia \[[@bib1],[@bib3]\]. In these patients also high incidence and mortality rates could be observed \[[@bib1],[@bib3]\].

In our report both patients died because of ongoing ARDS with multiorgan failure.

Growth of *Aspergillus spp.* in a respiratory culture from an ICU patient, is often interpreted as colonization rather than infection. Typical other diagnostics for IPA like biopsy or imaging technics may be more challenging in critically ill COVID-19 patients for several reasons.

Therefore, additionally testing of BAL-specimens for GM is easy, and the specifity of an ODI-cut-off of \>1·0 is about 90% to detect IPA \[[@bib4], [@bib5]\].

Early and sufficient antifungal medication is the cornerstone for effective IPA treatment. Our patients were treated with liposmal amphotericin-B (3mg/kg) because of multiorgan failure including hepatic failure, however, voriconazole and isavuconazole are sufficient alternatives.

In conclusion, Covid-19 associated invasive pulmonary aspergillosis (CAPA) may lead to a poor outcome even in immune competent individuals.

Further studies are needed to indicate if CAPA is a relevant complication in critically ill patients with severe COVID-19 pneumonia.
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[^1]: CrP (C reactive protein); IL6 (Inteleukin 6); PCT (Procalcitonin); LDH (Lactat dehydrogenases).
